Pfizer (PFE) and Arvinas (ARVN) delay Phase 3 trial for breast cancer therapy vepdegestrant to January 2025, citing trial status
https://seekingalpha.com/news/4305935-pfizer-arvinas-delay-breast-cancer-trial
Pfizer (PFE) and Arvinas (ARVN) delay Phase 3 trial for breast cancer therapy vepdegestrant to January 2025, citing trial status
https://seekingalpha.com/news/4305935-pfizer-arvinas-delay-breast-cancer-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.